All Posts Tagged With: "SHPGY"
(SHPGY) Shire and Sangamo BioSciences Cut a Deal
Shire plc (SHPGY) and Sangamo BioSciences, Inc. (SGMO) recently entered into a collaboration and license agreement for the development...
(BGC) Company News for August 3, 2011 – Corporate Summary
• Westlake Chemical Corporation (NYSE:WLK) posted Q2 EPS of $1.21, beating analysts’ estimates of $1.19 per share. Revenues rose 13% year-over-year to $925.0 million
• Engineering company Foster Wheeler...
(WPI) Watson Pharmaceuticals Entangled in Legal Dispute
The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement...
(SHPGY) Shire Entangled in Legal Dispute
The legal tussle between Shire (SHPGY), Sandoz, Inc. — the generic arm of Novartis (NVS) and Amneal Pharmaceuticals — intensified...
(ABT) Abbott Labs and Reata Pharmaceuticals Present New Phase II Data
Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently announced the presentation of new phase II data on bardoxolone methyl. In addition to being posted online in The New England Journal of...
(SHPGY) Shire to Produce More Replagal
UK-based Shire (SHPGY) recently announced that the European Medicines Agency (EMA) has increased the company’s manufacturing flexibility for Replagal (agalsidase alfa), an enzyme replacement therapy approved...
(SHPGY) Shire’s Firazyr Earns FDA Panel Backing
Recently, the Pulmonary-Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and recommended the US approval of Shire’s (SHPGY) Firazyr (icatibant).
Shire...
(ABT) Abbott Labs’ Bardoxolone in Phase III Trials
Abbott Labs (ABT) and partner Reata Pharmaceuticals, Inc. recently commenced a pivotal phase III study with bardoxolone methyl. Bardoxolone methyl’s safety and efficacy will be evaluated in patients with...
(SNY) Sanofi-Aventis Acquires Genzyme – Acquisition to Create New Source of Growth at Sanofi
Sanofi-Aventis (SNY) recently completed its acquisition of biotech company Genzyme Corporation. With the completion of the acquisition, Genzyme, now a wholly-owned subsidiary of Sanofi, will be Sanofi’s...
(SHPGY) Shire and Watson Pharmaceuticals in Patent Legal Battle
The legal tussle between Shire (SHPGY) and Watson Pharmaceuticals Inc. (WPI) intensified with the Ireland based Shire filing a case of...
(PLX) Protalix BioTherapeutics Sees FDA Setback for Gaucher Drug
Protalix BioTherapeutics, Inc. (PLX) was dealt a huge blow recently with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for the company’s Gaucher disease candidate, taliglucerase...
(WPI) Watson Pharmaceuticals Quarterly Earnings Report Outperforms Expectations
Watson Pharmaceuticals Inc.‘s (WPI) fourth quarter 2010 earnings (excluding special items) of $0.93 per share were in line with the Zacks Consensus Estimate and $0.08 above the year-ago earnings. Earnings,...
(PFE) Pfizer and Protalix BioTherapeutics Seek EU Approval
Pfizer (PFE) and its partner Protalix BioTherapeutics Inc. (PLX) recently announced that they have submitted the Marketing Authorization...
(SHPGY) Shire Beats Earnings Expectations – Increases Earnings Outlook
Shire plc (SHPGY) posted earnings of $1.16 per American Depositary Share (ADS) during the third quarter of 2010, beating the Zacks Consensus Estimate of 98 cents and the year-ago earnings of 49 cents per...
(SNY) Sanofi-Aventis Makes Hostile Bid for Genzyme
French pharma giant Sanofi-Aventis (SNY) recently went hostile with its bid to acquire biotech company Genzyme Corporation (GENZ). Sanofi...
(GENZ) Genzyme Rejects Sanofi-Aventis’ Aquisition Offer
Genzyme Corp. (GENZ) recently rejected Sanofi-Aventis’ (SNY) offer to acquire the company for $69 per share. Earlier in the day, Sanofi...
(SHPGY) Shire Plc Earns European Approval for Vpriv
Recently, Shire Plc. (SHPGY) received a boost when the European Commission approved its Gaucher disease product Vpriv (velaglucerase alfa) for marketing in 30 European countries. The decision to approve...
(SHPGY) Shire Drug ProAmatine’s Approval to be Withdrawn by US Food and Drug Administration
The US Food and Drug Administration (FDA) recently announced that it plans to withdraw the approval of Shire plc’s (SHPGY) ProAmatine. The drug is used to treat low blood pressure (orthostatic hypotension).
The...
(SHPGY) Shire plc Second Quarter 2010 Earnings Beat – Updates Outlook
Shire plc (SHPGY) posted earnings of $1.03 per American Depositary Share (ADS) during the second quarter of 2010, beating the Zacks Consensus Estimate of 88 cents and the year-ago earnings of 60 cents per...
(GENZ) Genzyme Second Quarter 2010 Earnings Miss by a Wide Margin
Genzyme Corporation (GENZ) reported second quarter earnings of 6 cents per share (excluding one-time items but including the impact of stock-based compensation expense), well below the Zacks Consensus Estimate...
(SHPGY) Shire plc Hears Good News From European Medicines Agency
Recently Shire plc (SHPGY) announced that its Gaucher disease product VPRIV (velaglucerase alfa) has received a favorable opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products...
(GENZ) Genzyme Corporation Earnings Scorecard
Following the release of first quarter results on April 21, 2010, several analysts covering Genzyme Corporation (GENZ) have lowered their earnings estimates for 2010 and 2011. Genzyme is still suffering from...
(GENZ) Genzyme First Quarter Earnings Beat by a Penny
Genzyme Corporation (GENZ) reported first quarter earnings of 24 cents per share, above the Zacks Consensus Estimate of 19 cents but well below the year-ago earnings of 70 cents.
With the company facing...
(SHPGY) Shire Presents Positive Data on Vpriv
Shire Plc. (SHPGY) recently presented positive phase III data on its Gaucher disease product, Vpriv. The trial was conducted to study the safety of switching patients from Genzyme’s (
(GENZ) Genzyme Corporation Sees FDA Consent Decree Likely
Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action...
(GENZ) Genzyme Likely to See FDA Enforcement Action
Just when Genzyme Corp. (GENZ) was slowly making some progress in addressing its manufacturing issues, the company announced that the US Food and Drug Administration (FDA) intends to take enforcement action...
(GENZ) Hospira Inks Manufacturing Deal with Genzyme
Genzyme Corp. (GENZ) has entered into a contract manufacturing agreement with Hospira (HSP) for its key drugs Incorporatedluding Cerezyme...
(SHPGY) Shire Seeks U.S. Food and Drug Administration Approval
Shire Plc (SHPGY) recently submitted a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) for Replagal (agalsidase alfa) meant for treating the genetic disorder Fabry disease.
Replagal...
(PLX) Protalix Biotherapeutics’ Drug Advances
Good news for Protalix Biotherapeutics (PLX) once again! The company completed the submission of its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for taliglucerase alfa, which...
(PFE) Bayer Advances on Alzheimer’s Plan
Alzheimer’s disease (AD) is a devastating neuro-degenerative disease that affects people over the age of 60. The onset of the disease is often so gradual and the early signs are so mild that they are often mistaken as common traits of ageing.
Early detection of the...